Cibus Q3 2021 Earnings Report
Key Takeaways
Calyxt reported a revenue of $7.8 million, a gross profit of negative $0.5 million, and a net loss of $7.3 million for Q3 2021. The company also launched a new strategic direction focusing on plant-based synthetic biology solutions and commissioned its first pilot BioFactory.
Launched a new strategic initiative focusing on engineering synthetic biology solutions for a diversified customer base.
Commissioned the first pilot BioFactory, expected to be online by the end of 2021.
Appointed IBM’s Global Chief Artificial Intelligence Officer, Dr. Seth Dobrin, to Calyxt’s Scientific Advisory Board.
Launched a $50.0 million at-the-market (ATM) share issuance program, raising $3.7 million in proceeds as of the report date.
Cibus
Cibus
Forward Guidance
No specific forward guidance was provided in the report. The company is focusing on its new strategic direction and the development of its PlantSpring technology platform and BioFactory production system.